2-仲丁基吡嗪(仲丁基吡嗪) | 29460-93-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-仲丁基吡嗪(仲丁基吡嗪)
• 中文别名: 2-仲丁基吡嗪
• 英文名称: s-Butylpyrazin
• 英文别名: sec-butyl-pyrazine；2-Sec-butylpyrazine；2-butan-2-ylpyrazine
• CAS: 29460-93-3
• 化学式: C₈H₁₂N₂
• mdl: MFCD02684323
• 分子量: 136.197
• InChiKey: NFFQZEXYZVZKNN-UHFFFAOYSA-N

物化性质

• 沸点：
  191.4±20.0 °C(Predicted)
• 密度：
  0.955±0.06 g/cm3(Predicted)
• 保留指数：
  1040;1040

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

制备方法与用途

用途：用于制作日用香精和食用香精。

反应信息

• 作为产物：
  描述：

  s-Butyl 2-pyrazinyl-sulfon 以34%的产率得到
  参考文献：
  名称：

  KONAKAHARA T.; GOKAN K.; IWAMA M.; TAKAGI Y., HETEROCYCLES, 1979, 12, NO 3, 373-376

  摘要：

  DOI：

文献信息

• [EN] HEPATITIS B ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX DE L'HÉPATITE B
  申请人：ENANTA PHARM INC

  公开号：WO2017015451A1

  公开（公告）日：2017-01-26

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A1-Y-A2-Z-L-R (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了化合物的结构式（I），或其药用可接受的盐、酯或前药：X-A1-Y-A2-Z-L-R（I），这些化合物能够抑制由乙型肝炎病毒（HBV）编码的蛋白质，或干扰乙型肝炎病毒的生命周期功能，同时也可作为抗病毒药物使用。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给受试者投予包含本发明化合物的药物组合物来治疗HBV感染的方法。
• OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME
  申请人：Yamashita Dennis

  公开号：US20120245181A1

  公开（公告）日：2012-09-27

  This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.

  这种应用描述了可以作为阿片受体配体的化合物，这些化合物可以用于治疗例如疼痛和与疼痛相关的疾病。
• ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS
  申请人：Boger Dale L.

  公开号：US20110183947A1

  公开（公告）日：2011-07-28

  The invention provides a series of -αketoheterocyclic compounds, for example, compounds of formula (I). The compounds can inhibit fatty acid amide hydrolase and can be useful for treatment of malconditions modulated by fatty acid amide hydrolase. The invention further provides methods of making compounds of formula (I), useful intermediates for the preparation of compounds of formula (I), and methods of using compounds of formula (I) and compositions thereof.

  本发明提供了一系列-α酮杂环化合物，例如，公式（I）的化合物。这些化合物可以抑制脂肪酸酰胺水解酶，并可用于治疗由脂肪酸酰胺水解酶调节的异常情况。本发明还提供了制备公式（I）化合物的方法，用于制备公式（I）化合物的有用中间体，以及使用公式（I）化合物及其组成物的方法。
• ACTINIC-RAY- OR RADIATION-SENSITIVE RESIN COMPOSITION AND METHOD OF FORMING PATTERN USING THE COMPOSITION
  申请人：Takahashi Hidenori

  公开号：US20120156618A1

  公开（公告）日：2012-06-21

  According to one embodiment, an actinic-ray- or radiation-sensitive resin composition includes a resin (P) containing not only at least one repeating unit (A) that when exposed to actinic rays or radiation, is decomposed to thereby generate an acid and is expressed by any of general formulae (I) to (III) below but also a repeating unit (B) containing at least an aromatic ring group provided that the repeating unit (B) does not include any of those of general formulae (I) to (III). (The characters used in general formulae (I) to (III) have the meanings mentioned in the description.)

  根据一种实施例，一种感光射线或辐射敏感的树脂组合物包括树脂（P），该树脂不仅包含至少一个重复单元（A），当暴露于感光射线或辐射时，分解从而产生酸，并由下列任一通式（I）至（III）表示，而且还包括一个重复单元（B），其中至少包含一个芳香环基团，前提是重复单元（B）不包括通式（I）至（III）中的任何一个。（通式（I）至（III）中使用的字符在描述中有所提及。）
• CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE
  申请人：Ng Simon C.

  公开号：US20100130490A1

  公开（公告）日：2010-05-27

  Benzoxazole and benzothiazole compounds and their oxides, esters, prodrugs, solvates, and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF 1R.

  本发明公开了苯并噁唑和苯并噻唑化合物及其氧化物、酯、前药、溶剂化物和药学上可接受的盐。本发明还公开了该化合物的组合物，其可以单独使用或与至少一种额外治疗剂联合使用，并与药学上可接受的载体一起使用。该实施例可用于抑制细胞增殖，抑制肿瘤的生长和/或代谢，治疗或预防癌症，治疗或预防退变性骨疾病，如类风湿性关节炎，并/或抑制分子，如CSF 1R。

表征谱图